89Bio, Inc. Stock Price, News & Analysis

On July 12, 2024, 89bio, a clinical-stage biopharmaceutical firm, announced the approval of non-qualified stock options for six new employees. The compensation committee of the board of directors granted these options on July 9, 2024, under the 2023 Inducement Plan, aligning with Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of 125,000 shares at the closing price of the company's stock on the grant date. These options will vest over four years: 25% after one year of employment and the remaining shares in 12 equal quarterly installments, contingent on continued employment.

89bio announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4) by its Compensation Committee. The grants, totaling 25,500 shares of common stock, were extended to two new employees on June 10, 2024, as part of the company's 2023 Inducement Plan. The exercise price for these stock options matches 89bio's closing stock price on the grant date. These grants will vest over four years, with 25% vesting after one year, followed by quarterly vesting contingent upon continued employment.

89bio, a clinical-stage biopharmaceutical company, will present 48-week data from its Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) at the EASL International Liver Congress in Milan, Italy, from June 5 to 8, 2024. The data highlights pegozafermin as the first FGF21 analog showing positive, sustained benefits over 48 weeks in patients with advanced MASH. The presentation will cover the drug's efficacy, tolerability, and improvements in liver health markers, and will be delivered by Dr. Rohit Loomba on June 8.

89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting accelerated approval in the U.S. and Europe. The trial's primary goal is to observe clinical outcome events for confirmatory or full approval. The ENLIGHTEN-Cirrhosis trial builds on promising Phase 2b results showing improvements in liver health markers, aiming to meet the urgent need for effective therapies in MASH with compensated cirrhosis.

89bio, Inc. announced the approval of non-qualified stock options for four new employees under the 2023 Inducement Plan. The options allow the purchase of 48,150 shares of the Company's common stock at the closing price on May 6, 2024. The options will vest over a four-year period, contingent on continued employment.

89bio, Inc. (Nasdaq: ETNB) reported its Q1 2024 financial results, highlighting the initiation of Phase 3 trials for pegozafermin in MASH patients, EMA's PRIME status, and positive data from the ENLIVEN Phase 2b Trial. The company also entered a collaboration agreement for commercial supply and appointed a new Board member. Financially, 89bio had $562.3 million in cash, R&D expenses increased to $47.4 million, G&A expenses rose to $9.8 million, resulting in a net loss of $51.7 million.

89bio, Inc. (Nasdaq: ETNB) will participate in the BofA Securities 2024 Health Care Conference to present their innovative therapies for liver and cardiometabolic diseases. The presentation is scheduled for May 15, 2024, at 2:20 PM PDT.

89bio, Inc. (Nasdaq: ETNB) will host a key opinion leader event discussing pegozafermin's potential in advanced metabolic dysfunction-associated steatohepatitis (MASH) on May 16, 2024, featuring expert hepatologist Arun Sanyal, M.D. The webinar will cover the ENLIGHTEN-Cirrhosis trial and the commercial prospects for pegozafermin in advanced MASH.